SEC Form 4 · accession 0001127602-18-024251
Medtronic plc · MDT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rob Ten Hoedt
Officer — EVP & President EMEA
Period of report
Jul 30, 2018
Accepted (ET)
Aug 1, 2018 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001613103
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Jul 30, 2018 | A | 9,730 | $0.00 | A | 71,062 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $89.08 | Jul 30, 2018 | A | 58,745 | A | Jul 30, 2019 | Jul 30, 2028 | Ordinary Shares | 58,745 | 58,745 | D |
| Stock Option (Right to Buy)F3 | $89.08 | Jul 30, 2018 | A | 1,695 | A | Jul 30, 2019 | Jul 30, 2028 | Ordinary Shares | 1,695 | 1,695 | D |
Explanation of responses
- F1The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee.
- F2This balance increased by 906 shares due to exempt transactions such as dividend reinvestment.
- F3These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.